Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Clinical safety results reported for Isis c-Raf kinase antisense oligonucleotide

Aug. 2, 2000

Antisense compounds from Isis modulate the expression of Akt-1

Aug. 1, 2000

Oxigene completes phase I trials of declopramide

Aug. 1, 2000

Cancer chemoresistance may be weakened by inhibitors of fibroblast growth factors

Aug. 1, 2000

Licensing opportunity from NIH: treating renal cell carcinoma with FGF-5

Aug. 1, 2000

Celecoxib in familial adenomatous polyposis

Aug. 1, 2000

Recently issued patent covers new compounds for estrogen-related conditions

July 31, 2000

Anticancer combinations with synergistic activity

July 31, 2000

Viragen signs collaboration for cancer vaccine development

July 31, 2000

New inhibitors of Ras oncogene farnesylation in the Merck pipeline

July 28, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....